BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating
Esperion Therapeutics Analyst Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $7
Esperion Therapeutics Analyst Ratings
BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating
Esperion Therapeutics Analyst Ratings
Esperion Therapeutics Analyst Ratings
Esperion Therapeutics Analyst Ratings
Esperion Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Esperion Therapeutics Analyst Ratings
Northland Securities Sticks to Their Hold Rating for Esperion (ESPR)
Esperion Therapeutics Analyst Ratings
Esperion Therapeutics Analyst Ratings
Esperion Therapeutics Analyst Ratings
Esperion Therapeutics Analyst Ratings
Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $8
Esperion Therapeutics Analyst Ratings
Needham Reiterates Buy on Esperion Therapeutics, Maintains $9 Price Target
No Data
No Data